Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Completed · Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have acute myeloid leukemia.
Key facts
- Study ID
- NCT00005795
- Run by
- Northwestern University
- People needed
- 11
- Starts
- 2000-02-01
- Expected to finish
- 2002-07-01
- Last updated by the study team
- 2012-06-11
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.